Ozempic and longevity

GLP-1 drugs such as Ozempic, Wegovy and Mounjaro are lab-made versions of a gut hormone that makes you feel full. Most are a weekly injection, and they were built for type 2 diabetes. They help with weight loss, and in high-risk patients they also protect the heart and kidneys.^{[1, 3, 18]} All of them are prescription medicines with real risks. This guide is not medical advice, so any decision to take one belongs in a conversation with your doctor.

The natural hormone, GLP-1 (glucagon-like peptide-1), is released by your gut after a meal. It tells your brain you have eaten enough, slows how fast your stomach empties and helps control insulin. The drugs copy that signal but stay in the body far longer than the hormone itself.^[16] These are the main ones:

• Semaglutide, sold as Ozempic for type 2 diabetes and as Wegovy for weight loss, taken as a weekly injection.^{[16, 49]} Since July 2026 the EU has also approved a once-daily Wegovy pill (oral semaglutide, up to 25 mg) and a single-dose 7.2 mg pen.^[16]
• Tirzepatide, sold in the EU as Mounjaro for type 2 diabetes and weight loss, works on two receptors instead of one: GLP-1 plus a second gut hormone, GIP.^[32] In the US its obesity brand is Zepbound.^[35]
• Liraglutide is the older drug of the group, injected daily.

Weight loss is what moved these diabetes drugs into obesity care. In the main obesity trials, people lost about 15 percent of their body weight on semaglutide 2.4 mg and up to about 21 percent on tirzepatide.^{[18, 19]} That was enough for regulators to clear them for obesity as well. It is also where the longevity question starts: do the drugs help people live longer or stay healthier than the lost weight alone would explain?

Newer drugs on the way

Two newer drugs from Eli Lilly may widen the choice. Orforglipron is a pill, sold in the US as Foundayo, and retatrutide is a weekly injection that works on three receptors at once (GLP-1, GIP and glucagon).^{[22, 31]} The table puts their main obesity results next to today's drugs. Because the trials ran for different lengths in different people, read the weight-loss column as a rough guide rather than a ranking.

Sources: STEP 1, SURMOUNT-1, ATTAIN-1 and TRIUMPH-1 for weight loss, the regulators' pages and databases for status [16, 18, 19, 22, 28–31, 54, 55]. Placebo groups lost a few percent in each trial, about 2 percent in the orforglipron trial and 4 percent in the retatrutide trial^{[22, 31]}

Neither newer drug can be prescribed in Germany yet. On 15 October 2026 the EMA's medicines committee (CHMP) recommended approving Foundayo in the EU for adults with obesity, or overweight plus a weight-related condition, and for type 2 diabetes.^[28] The European Commission still has to decide, so as of October 2026 there is no prescription in Germany or Austria and no German price.^[28] Retatrutide is further behind: its main trial, TRIUMPH-1, is published, with stomach and gut problems as the most common side effects.^[31] The drug itself is not approved, so anything sold online as retatrutide is an unapproved product of unknown content.

How the Wegovy pill is taken

The Wegovy pill is prescription-only, like the injections, and approved for adults only. It works only if you take it on an empty stomach after at least 8 hours without food, with a sip of water. Then wait at least 30 minutes before eating, drinking or taking other pills, and take one tablet a day, never two.^[16]

Losing weight and living longer are linked, but they are not the same thing, and the longevity question for GLP-1 drugs sits in the gap between them. Large observational studies, which watch people rather than test a treatment, link obesity to shorter lives. They measure it by body mass index (BMI), your weight relative to your height. At a BMI of 30 to 35, median survival was 2 to 4 years shorter, and at 40 to 45 about 8 to 10 years shorter.^[42] Reversing obesity should, in theory, win some of those years back.

Whether it does depends on more than the number on the scale, because weight-loss studies have not all ended the same way. Bariatric surgery removes far more weight for far longer. In the Swedish SOS study, it was linked to roughly 20 to 30 percent fewer deaths over more than 10 years.^[6] The study was controlled but not randomised, so patients were not assigned to surgery by chance. Look AHEAD, an intensive programme of diet, exercise and coaching for people with type 2 diabetes, brought much smaller weight loss and did not reduce heart events. The trial was stopped early because continuing was unlikely to show a benefit.^[7]

Those two studies differ in how much weight came off, in design and in what they measured. So they cannot tell us whether the method, the amount or the durability of the weight loss made the difference. What they do show is that more weight lost for longer went with fewer deaths in the surgery study.^[6]

Even where weight loss helps, it has a cost, because part of what you lose is lean mass rather than fat. In scan substudies, about a quarter of the weight lost on tirzepatide was lean mass.^[26] On semaglutide, lean mass fell by about 10 percent and fat mass by about 19 percent.^[27] By our own calculation from those averages, that is roughly a third of the weight lost.

That lean-mass figure overstates the muscle loss a little. The scan used in these studies (DEXA) counts as lean mass everything that is neither fat nor bone, so it includes water, organs and other soft tissue as well as skeletal muscle. Strength training plus enough protein is the best-supported way to limit the loss, and protein alone is not enough.^[33] Neither guarantees you keep all your muscle. How much the loss matters for strength and mobility in the long run is still being studied. Our guide on keeping muscle on GLP-1 covers the practical side.

All of that concerns people who start with excess weight. The outcome trials of GLP-1 drugs enrolled people with overweight or obesity, diabetes, or heart, kidney or Alzheimer's disease. None of them tested whether the drugs help healthy, normal-weight people live longer.^{[1, 3, 15]} For someone already at a healthy BMI, any benefit is an extrapolation. The firm human evidence on these drugs still comes from patients who started at high risk.

The firmest evidence that a GLP-1 drug lowers deaths comes from people with type 2 diabetes and chronic kidney disease. In the FLOW trial, weekly semaglutide 1 mg cut their deaths from any cause by 20 percent.^[3] The trial's main goal, a count of serious kidney problems or deaths from kidney or heart causes, fell by about a quarter, and major heart events fell too.^[3] Because the death result was tested in an order the researchers had fixed in advance, it counts as a finding rather than a hint.^[3] For type 2 diabetes in general, a pooled analysis of eight heart-outcome trials points the same way. It found about 12 percent fewer deaths from any cause on GLP-1 drugs.^[52]

SELECT, by contrast, studied people without diabetes, but all of them already had heart or blood-vessel disease.^[1] They had overweight or obesity and had already had a heart attack, a stroke or narrowed leg arteries that caused symptoms (peripheral artery disease). On semaglutide 2.4 mg weekly, heart attacks, strokes and heart deaths fell by 20 percent compared with placebo.^[1] That was the trial's main goal, measured over a little more than three years on average.

SELECT also counted 19 percent fewer deaths from any cause, but that number is weaker than it looks.^[1] The trial tested its goals in a fixed order. Because an earlier step had already missed, the death result is a lead to follow up rather than proof. The heart result itself is firm, and a smaller trial extends it to heart failure. In people with obesity and the kind of heart failure where the heart pumps but stays stiff (STEP-HFpEF), semaglutide improved symptoms and exercise capacity.^[2]

Tirzepatide's heart trial was set up differently, against another GLP-1 drug, dulaglutide, rather than a placebo. In people with type 2 diabetes and heart disease, it prevented heart attacks, strokes and heart deaths as well as dulaglutide did but was not proven better.^[40] The EU label now describes those results without approving tirzepatide for heart protection.^[32]

The liver: a third organ with an approval

Besides the heart and kidneys, semaglutide now also has an approval for the liver. It covers MASH (metabolic dysfunction-associated steatohepatitis), fatty liver that has turned into inflammation and scarring. The approval is for the stage called F2–F3 fibrosis, meaning moderate to advanced scarring that has not yet become cirrhosis.

• US: on 15 August 2025 the FDA approved Wegovy for MASH with F2–F3 fibrosis without cirrhosis, based on the first part of the ESSENCE trial.^{[21, 44]}
• EU: the European Commission granted conditional approval on 26 March 2026 under the brand name Kayshild.^[24] Conditional means more proof is owed: results of the ongoing ESSENCE trial on clinical events are expected around 2029.^[43]
• Tirzepatide has no MASH approval in the EU as of October 2026, despite social-media claims to the contrary; the published evidence so far is a phase 2 trial.^[11]

Does semaglutide slow ageing itself?

All of these results, the liver included, come from sick people, so they show protected organs rather than slower ageing. The first direct test of ageing came from mice: researchers gave semaglutide to 20-month-old females, retirement age for a mouse, and treated them for life. Their median lifespan rose by about 12 percent.^[12] The treated mice also explored more, remembered their way around better and controlled their blood sugar better than mice whose calories were cut to match.^[12] That comparison group was there to separate the drug from simply eating less. Mice are not people, though, and only females were tested.

In people, the ageing evidence so far comes from blood tests rather than from lives followed to the end. Epigenetic clocks read chemical tags on your DNA to estimate how your body is ageing, and one of them, DunedinPACE, estimates how fast you age. In a placebo-controlled trial in adults with HIV-related fat build-up, several of these clocks ran slower on semaglutide, DunedinPACE by 9 percent.^[13] That result came from an after-the-fact analysis of 84 participants, because epigenetic ageing was not a planned goal of the trial.^[13] A slower clock is a biomarker, a measurable sign in the blood, and not yet a longer life.

What we still don't know

Neither the mouse result nor the blood clocks show how long people live on these drugs, and several questions stay open:

• Direct human lifespan data over 10 or more years.
• The effect in healthy people at a normal weight.
• Safety over several decades of use.
• Whether the benefits last after stopping, since a large part of the lost weight returns within one to two years.^{[5, 17]}
• The brain: in two phase 3 trials, evoke and evoke+, oral semaglutide did not slow early Alzheimer's disease.^[15]

SELECT-LIFE adds a little to the first question. It followed about 3,400 SELECT participants by questionnaire after they stopped the study drug and was completed in August 2025.^[46] Because it only observes people, a firm answer on lifespan would still need a trial built for it.

GLP-1 drugs are prescription medicines with real side effects, and the most common one is nausea. About 44 percent of people on the Wegovy injection reported it over the 68-week STEP trials, and 47 percent on the Wegovy pill.^[16] It is mostly mild to moderate, short-lived and tied to dose increases, and it often comes with diarrhoea, constipation or vomiting.^[16] Next to this common stomach trouble sit rarer but serious risks, such as pancreatitis, gallstones and a very rare form of sudden vision loss (NAION).

Common (roughly 1 in 4 to 1 in 2 users at obesity doses).^[16]:

• Nausea, especially in the first weeks and after a dose increase
• Diarrhoea or constipation
• Vomiting
• Loss of appetite, which is the intended effect but can tip into eating too little

Less common but serious:

• Pancreatitis (an inflamed pancreas): severe, persistent upper-belly pain needs medical help right away, and if pancreatitis is confirmed the drug is not restarted^[16]
• Gallbladder problems, including gallstones and an inflamed gallbladder.^[16]
• Slow stomach emptying and anaesthesia. Food left in the stomach can get into the lungs under anaesthesia (pulmonary aspiration), so tell your anaesthetist you take a GLP-1 drug before any surgery or deep sedation. Five specialist societies have replaced the earlier blanket one-week pause with a case-by-case approach.^[20] The team weighs your risk and may change your diet beforehand or check your stomach with ultrasound instead of stopping the drug automatically.^[20]
• Acute kidney injury from dehydration, if nausea or vomiting stops you drinking enough.^[16]
• Medullary thyroid carcinoma (MTC) and MEN 2 (multiple endocrine neoplasia type 2, an inherited tumour syndrome). The US labels carry a boxed warning and rule the drugs out if you or a close relative has had MTC or MEN 2.^{[47, 48]} The EU label has no such warning: it mentions thyroid C-cell tumours only in rodent studies and rates their relevance for humans as low.^[16] With that history, raise it with your doctor before starting.
• NAION (non-arteritic anterior ischaemic optic neuropathy), sudden vision loss when blood flow to the optic nerve drops. A first single-hospital study suggested a several-fold higher risk on semaglutide,^[4] but much larger analyses found a smaller rise.^{[9, 10]} In June 2025 the EMA's safety committee classed NAION as a very rare side effect of semaglutide, affecting up to 1 in 10,000 people.^[25] The EU label puts it at about one extra case per 10,000 person-years of treatment, where one person treated for one year counts as one person-year.^[16] If you notice sudden, painless vision loss, see an eye doctor urgently; if NAION is confirmed, semaglutide is stopped.^[16]
• Worsening diabetic eye disease (retinopathy) in people who already have it.^[16]
• Muscle loss if you do not plan around it.^{[26, 27]}
• Lower bone density. In a small one-year trial in adults with an increased fracture risk, semaglutide lowered bone density at the spine and hip compared with placebo, alongside the weight loss.^[53] Whether that leads to more fractures is not known, so if you have osteoporosis or a high fracture risk, ask your doctor about checking your bones.

Mental health. Reports of mood changes and suicidal thoughts led regulators to review these drugs. The EMA's safety committee concluded in April 2024 that the evidence does not support a causal link.^[36] In January 2026 the FDA found no increased risk and asked for the suicidality warning to be removed from the US labels of Wegovy, Zepbound and Saxenda.^[35] If you notice new or worsening low mood or suicidal thoughts, still tell your doctor straight away.

Fakes. Counterfeit pens are a safety risk of their own. In October 2023, during the Ozempic shortage, the EMA warned that falsified Ozempic pens with German labels had turned up at wholesalers in Germany and Austria.^[45] None were known to have reached patients through legal pharmacies, and the safe course is to fill prescriptions only at licensed pharmacies, online ones included.^[45]

Who needs extra care or should not take it

If you take insulin or a sulfonylurea (an older type of diabetes tablet), adding a GLP-1 drug raises the risk of low blood sugar. Your doctor will usually lower that dose at the start, and you need to check your glucose.^{[16, 32]} Semaglutide does not replace insulin.^{[16, 51]}

The Wegovy EU label does not recommend the drug in these situations.^[16]:

• Type 1 diabetes.
• Severe kidney impairment, meaning an eGFR (a blood-test estimate of how well the kidneys filter) under 30.
• Severe liver impairment.
• Severe heart failure (NYHA class IV, with symptoms even at rest).
• Severe gastroparesis, a stomach that empties very slowly.
• Unstable diabetic eye disease.
• Use together with another GLP-1 drug or other weight-loss medicine.

The Ozempic label for type 2 diabetes is less strict on two of these points. It needs no dose change even in severe kidney impairment, and in severe liver impairment it asks for caution rather than advising against use^[51] If you have had pancreatitis, the drug is used only with caution.^[16] On warfarin or a similar blood thinner, your INR (a blood-clotting test) needs checking more often when you start.^[16]

Whether a GLP-1 drug makes sense for you depends on where you start. With obesity or type 2 diabetes, these drugs are among the most effective treatments available. They bring large weight loss and, in high-risk groups, proven heart and kidney benefits.^{[1, 3, 18, 19]} That makes them worth discussing with a doctor, ideally one with endocrinology or cardiology expertise.

At a normal weight, taking them purely for longevity is speculation. Low-dose off-label use, meaning use outside the approved purpose, gets talked about in longevity circles, especially in the US. Yet no trial has shown a benefit for healthy, normal-weight people. The known risks (muscle loss, stomach problems, rare serious events) do not shrink because the hoped-for benefit is unproven. In Germany, statutory insurance does not pay for it, because the law excludes weight-loss drugs.^[8] Medicines used outside their approved purpose are covered only in narrow exceptions, for serious diseases with no other treatment.^[61] A prescription for longevity would therefore be a private one you pay yourself.

Who qualifies and who pays in Germany

In Germany, Wegovy is approved for adults in two situations, both based on BMI (your weight relative to your height).^[16]:

• a BMI of 30 or more on its own, or
• a BMI of 27 to under 30 plus at least one weight-related condition: blood-sugar problems (prediabetes or type 2 diabetes), high blood pressure, abnormal blood fats, obstructive sleep apnoea (breathing that keeps stopping during sleep) or heart disease.

Who pays depends on why you take it (Austria and Switzerland have different insurance rules):

• Obesity: statutory insurance never pays. The statutory health insurance (GKV) excludes Wegovy and Mounjaro for weight loss as lifestyle drugs^[8] Private insurers (PKV) can reimburse them when the treatment is medically necessary and within the approved use, as long as your contract does not exclude weight-loss drugs, so ask your insurer before you start.^[37] Either way, the prescription is a private one (Privatrezept) from your GP or a specialist obesity practice.
• Type 2 diabetes: reimbursed. The exclusion covers weight loss only, so GKV pays for Ozempic or Mounjaro on their approved diabetes indication, via your GP, diabetologist or internist.^{[8, 32]} Ozempic for weight loss without diabetes falls under the exclusion again.^[8]

If you pay yourself, expect roughly €170 to 490 per four weeks, depending on drug and dose (pharmacy prices as of October 2026). One pen or pack covers four weekly doses:

• Wegovy injection: about €173 at the starting dose, up to €384 for the 7.2 mg pens.^{[56, 57]}
• Mounjaro: about €207 for a 2.5 mg pen, up to €490 for a 15 mg pen, and a little less per pen in a pack of three [58–60].

Current prices per dose are in our cost comparison. The costs add up over time, because the weight tends to return when people stop.^{[5, 17]}

Contraception, pregnancy and breastfeeding

Tirzepatide (Mounjaro) briefly lowers blood levels of the contraceptive pill. The US label advises switching to a non-oral method or adding a condom for 4 weeks after starting and after each dose increase.^[47] The EU label, by contrast, calls the drop not clinically relevant.^[32] Semaglutide does not weaken the pill,^[16] but severe vomiting or diarrhoea can weaken any pill, so ask your gynaecologist.

Neither drug is meant for pregnancy. The EU labels say to stop semaglutide at least 2 months, and tirzepatide at least 1 month, before a planned pregnancy.^{[16, 32]} Wegovy should not be used while breastfeeding.^[16] The Mounjaro label says it could be considered during breastfeeding, so decide that with your doctor.^[32]

Warning signs that need help the same day

Some symptoms should not wait for the next appointment:

• Severe, persistent upper-belly pain, with or without vomiting. If pancreatitis is suspected the drug is stopped, and if it is confirmed it is not restarted. A raised lipase on its own, without symptoms, does not predict pancreatitis.^[16]
• Not keeping fluids down, feeling dizzy or dry, because dehydration can harm the kidneys.^[16]
• Gallbladder pain.^[16]
• Sudden, painless vision loss: see an eye doctor urgently.^[16]
• New or worsening low mood or suicidal thoughts.^[35]

Also tell your doctor promptly if you become pregnant, because neither drug is meant for pregnancy.^{[16, 32]} The same goes for a lump or swelling in your neck, trouble swallowing or lasting hoarseness, which the US labels name as thyroid warning signs.^{[47, 48]}

Before and during treatment

These are points to raise with your prescriber, not a do-it-yourself protocol. The first two, training and protein, we consider non-negotiable on any GLP-1 drug, because they are the best-supported way to limit muscle loss.^[33]

• Strength training at least three times a week plus at least 150 minutes of moderate aerobic exercise, adjusted to your fitness.^[33] Our exercise guide shows how to start.
• Enough protein. A joint advisory of four US obesity and nutrition societies names about 1.2 to 1.6 g per kg of body weight per day during active weight loss, or simply 80 to 120 g a day.^[33] With obesity, a per-kg target based on your actual weight overestimates what you need, and long-term intakes of 2 g per kg or more should be avoided.^[33]
• Protein with kidney disease. If you have chronic kidney disease, do not raise protein on your own; ask your kidney doctor. For adults with moderate to advanced kidney disease (stages G3 to G5) who are not on dialysis, the kidney guideline suggests about 0.8 g per kg a day, and no more than 1.3 g per kg if the disease may progress.^[34] On dialysis, or with frailty or muscle wasting, the target is set individually, and for frail older adults the guideline suggests considering more protein.^[34]
• Body composition. Measuring body composition (for example with DEXA or bioimpedance) and strength at the start and during treatment helps you and your doctor spot excessive muscle loss.^[33]
• Blood tests. Your doctor decides which tests you need and how often, depending on why you take the drug; for diabetes, HbA1c (a three-month blood-sugar average) and kidney function are routine.
• The first weeks. Nausea is common early, especially after a dose step. If stomach symptoms are significant, tell your prescriber before the next step, because the label allows delaying the increase or going back to the previous dose until you feel better.^[16]

Part of the weight lost is lean mass, so the one step we would not skip is a muscle plan agreed with your doctor before the first dose. That way strength training starts in the first week rather than after the scale has moved.